ID

32899

Description

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5); ODM derived from: https://clinicaltrials.gov/show/NCT00877890

Link

https://clinicaltrials.gov/show/NCT00877890

Keywords

Versions (1)
  1. 11/19/18 11/19/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 19, 2018

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes Mellitus NCT00877890

English

Eligibility Type 2 Diabetes Mellitus NCT00877890

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
has been diagnosed with type 2 diabetes mellitus
Description

Diabetes Mellitus, Non-Insulin-Dependent

Data type

boolean

Alias
UMLS CUI [1]
C0011860
has hemoglobin-specific a1c fraction (hba1c) of 7.1% to 11.0%, inclusive, at screening
Description

Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1]
C0474680
has a body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening
Description

Body mass index

Data type

boolean

Alias
UMLS CUI [1]
C1305855
has been treated with diet and exercise alone or in combination with a stable regimen of metformin (met), a sulfonylurea (su), a thiazolidinedione (tzd), a combination of metformin and an su, a combination of metformin and a tzd, or a combination of an su and a tzd for a minimum of 2 months prior to screening
Description

Diet therapy | Exercise | Metformin Stable | Sulfonylurea Stable | Thiazolidinediones Stable | Combined Modality Therapy

Data type

boolean

Alias
UMLS CUI [1]
C0012159
UMLS CUI [2]
C0015259
UMLS CUI [3,1]
C0025598
UMLS CUI [3,2]
C0205360
UMLS CUI [4,1]
C0038766
UMLS CUI [4,2]
C0205360
UMLS CUI [5,1]
C1257987
UMLS CUI [5,2]
C0205360
UMLS CUI [6]
C0009429
either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:
Description

Pharmaceutical Preparations Following Absent | Pharmaceutical Preparations Following Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332282
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0332282
UMLS CUI [2,3]
C0205360
hormone replacement therapy (female subjects)
Description

Hormone replacement therapy | Gender

Data type

boolean

Alias
UMLS CUI [1]
C0282402
UMLS CUI [2]
C0079399
oral contraceptives (female subjects)
Description

Contraceptives, Oral | Gender

Data type

boolean

Alias
UMLS CUI [1]
C0009905
UMLS CUI [2]
C0079399
antihypertensive agents
Description

Antihypertensive Agents

Data type

boolean

Alias
UMLS CUI [1]
C0003364
lipid-lowering agents
Description

Hypolipidemic Agents

Data type

boolean

Alias
UMLS CUI [1]
C0086440
thyroid replacement therapy
Description

Thyroid hormone replacement therapy

Data type

boolean

Alias
UMLS CUI [1]
C2242640
antidepressant agents
Description

Antidepressive Agents

Data type

boolean

Alias
UMLS CUI [1]
C0003289
drugs known to affect body weight, including prescription medications (e.g. orlistat [xenical®], sibutramine [meridia®], topiramate [topamax®]) and over the counter antiobesity agents
Description

Pharmaceutical Preparations Affecting Body Weight | orlistat | Xenical | sibutramine | Meridia | topiramate | Topamax | Over-the-counter Anti-Obesity Agents

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0005910
UMLS CUI [2]
C0076275
UMLS CUI [3]
C0732649
UMLS CUI [4]
C0074493
UMLS CUI [5]
C0635898
UMLS CUI [6]
C0076829
UMLS CUI [7]
C0723778
UMLS CUI [8,1]
C0013231
UMLS CUI [8,2]
C0376607
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
has ever been exposed to exenatide (exenatide once weekly [exenatide lar], exenatide bid, byetta, or any other formulation) or any glucagon-like peptide-1 (glp-1) analog
Description

Exposure to Exenatide | Exposure to Byetta | Exposure to GLP-1 analogues

Data type

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0167117
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C1636686
UMLS CUI [3,1]
C0332157
UMLS CUI [3,2]
C4301632
has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:
Description

Pharmaceutical Preparations Excluded

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0332196
any dipeptidyl peptidase 4 (dpp-4) inhibitor within 3 months prior to screening
Description

Dipeptidyl-Peptidase IV Inhibitors

Data type

boolean

Alias
UMLS CUI [1]
C1827106
alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (symlin®) within 30 days of screening
Description

alpha-Glucosidase Inhibitors | Meglitinide | nateglinide | Pramlintide | Symlin

Data type

boolean

Alias
UMLS CUI [1]
C1299007
UMLS CUI [2]
C0065880
UMLS CUI [3]
C0903898
UMLS CUI [4]
C0537551
UMLS CUI [5]
C1174780
insulin within 2 weeks of screening or for more than 1 week within 3 months of screening
Description

Insulin

Data type

boolean

Alias
UMLS CUI [1]
C0021641
systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including advair®) steroids known to have a high rate of systemic absorption
Description

CORTICOSTEROIDS FOR SYSTEMIC USE Oral | CORTICOSTEROIDS FOR SYSTEMIC USE Intravenous | CORTICOSTEROIDS FOR SYSTEMIC USE Intramuscular | Inhaled steroids | Steroids Intrapulmonary | Advair

Data type

boolean

Alias
UMLS CUI [1,1]
C3653708
UMLS CUI [1,2]
C1527415
UMLS CUI [2,1]
C3653708
UMLS CUI [2,2]
C1522726
UMLS CUI [3,1]
C3653708
UMLS CUI [3,2]
C1556154
UMLS CUI [4]
C2065041
UMLS CUI [5,1]
C0038317
UMLS CUI [5,2]
C1522224
UMLS CUI [6]
C0965130
Back to the top of the page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00877890

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
has been diagnosed with type 2 diabetes mellitus
boolean
C0011860 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
has hemoglobin-specific a1c fraction (hba1c) of 7.1% to 11.0%, inclusive, at screening
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
has a body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening
boolean
C1305855 (UMLS CUI [1])
Diet therapy | Exercise | Metformin Stable | Sulfonylurea Stable | Thiazolidinediones Stable | Combined Modality Therapy
Item
has been treated with diet and exercise alone or in combination with a stable regimen of metformin (met), a sulfonylurea (su), a thiazolidinedione (tzd), a combination of metformin and an su, a combination of metformin and a tzd, or a combination of an su and a tzd for a minimum of 2 months prior to screening
boolean
C0012159 (UMLS CUI [1])
C0015259 (UMLS CUI [2])
C0025598 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0038766 (UMLS CUI [4,1])
C0205360 (UMLS CUI [4,2])
C1257987 (UMLS CUI [5,1])
C0205360 (UMLS CUI [5,2])
C0009429 (UMLS CUI [6])
Pharmaceutical Preparations Following Absent | Pharmaceutical Preparations Following Stable
Item
either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:
boolean
C0013227 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0332282 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Hormone replacement therapy | Gender
Item
hormone replacement therapy (female subjects)
boolean
C0282402 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Contraceptives, Oral | Gender
Item
oral contraceptives (female subjects)
boolean
C0009905 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Antihypertensive Agents
Item
antihypertensive agents
boolean
C0003364 (UMLS CUI [1])
Hypolipidemic Agents
Item
lipid-lowering agents
boolean
C0086440 (UMLS CUI [1])
Thyroid hormone replacement therapy
Item
thyroid replacement therapy
boolean
C2242640 (UMLS CUI [1])
Antidepressive Agents
Item
antidepressant agents
boolean
C0003289 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Body Weight | orlistat | Xenical | sibutramine | Meridia | topiramate | Topamax | Over-the-counter Anti-Obesity Agents
Item
drugs known to affect body weight, including prescription medications (e.g. orlistat [xenical®], sibutramine [meridia®], topiramate [topamax®]) and over the counter antiobesity agents
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005910 (UMLS CUI [1,3])
C0076275 (UMLS CUI [2])
C0732649 (UMLS CUI [3])
C0074493 (UMLS CUI [4])
C0635898 (UMLS CUI [5])
C0076829 (UMLS CUI [6])
C0723778 (UMLS CUI [7])
C0013231 (UMLS CUI [8,1])
C0376607 (UMLS CUI [8,2])
Item Group
C0680251 (UMLS CUI)
Exposure to Exenatide | Exposure to Byetta | Exposure to GLP-1 analogues
Item
has ever been exposed to exenatide (exenatide once weekly [exenatide lar], exenatide bid, byetta, or any other formulation) or any glucagon-like peptide-1 (glp-1) analog
boolean
C0332157 (UMLS CUI [1,1])
C0167117 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C1636686 (UMLS CUI [2,2])
C0332157 (UMLS CUI [3,1])
C4301632 (UMLS CUI [3,2])
Investigational New Drugs
Item
has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening
boolean
C0013230 (UMLS CUI [1])
Pharmaceutical Preparations Excluded
Item
has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:
boolean
C0013227 (UMLS CUI [1,1])
C0332196 (UMLS CUI [1,2])
Dipeptidyl-Peptidase IV Inhibitors
Item
any dipeptidyl peptidase 4 (dpp-4) inhibitor within 3 months prior to screening
boolean
C1827106 (UMLS CUI [1])
alpha-Glucosidase Inhibitors | Meglitinide | nateglinide | Pramlintide | Symlin
Item
alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (symlin®) within 30 days of screening
boolean
C1299007 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0903898 (UMLS CUI [3])
C0537551 (UMLS CUI [4])
C1174780 (UMLS CUI [5])
Insulin
Item
insulin within 2 weeks of screening or for more than 1 week within 3 months of screening
boolean
C0021641 (UMLS CUI [1])
CORTICOSTEROIDS FOR SYSTEMIC USE Oral | CORTICOSTEROIDS FOR SYSTEMIC USE Intravenous | CORTICOSTEROIDS FOR SYSTEMIC USE Intramuscular | Inhaled steroids | Steroids Intrapulmonary | Advair
Item
systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including advair®) steroids known to have a high rate of systemic absorption
boolean
C3653708 (UMLS CUI [1,1])
C1527415 (UMLS CUI [1,2])
C3653708 (UMLS CUI [2,1])
C1522726 (UMLS CUI [2,2])
C3653708 (UMLS CUI [3,1])
C1556154 (UMLS CUI [3,2])
C2065041 (UMLS CUI [4])
C0038317 (UMLS CUI [5,1])
C1522224 (UMLS CUI [5,2])
C0965130 (UMLS CUI [6])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial